The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer. Issue 3 (March 2017)

• Record Type: Journal Article
• Authors: Zhang, Hongshuo; Fan, Yue; Xia, Lingling; Gao, Chunhui; Tong, Xin; Wang, Hanfu; Sun, Lili; Ji, Tuo; Jin, Mingyu; Gu, Bing; Fan, Bo
• Is Part Of: Tumor biology. Volume 39:Issue 3(2017)
• Publication Date: 2017-03
• Subjects: Bladder cancer -- proteomics -- diagnosis -- treatment -- prognosis; Cancer -- Periodicals; Oncology -- Periodicals; Tumors -- Periodicals; 616.994
• DOI: 10.1177/1010428317691183
• Languages: English
• ISSNs: 1010-4283

Abstract

Bladder cancer is the most common cancer of the urinary tract and can be avoided through proper surveillance and monitoring. Several genetic factors are known to contribute to the progression of bladder cancer, many of which produce molecules that serve as cancer biomarkers. Blood, urine, and tissue are commonly analyzed for the presence of biomarkers, which can be derived from either the nucleus or the mitochondria. Recent advances in proteomics have facilitated the high-throughput profiling of data generated from bladder cancer–related proteins or peptides in parallel with high sensitivity and specificity, providing a wealth of information for biomarker discovery and validation. However, the transmission of screening results from one laboratory to another remains the main disadvantage of these methods, a fact that emphasizes the need for consistent and standardized procedures as suggested by the Human Proteome Organization. This review summarizes the latest discoveries and progress of biomarker identification for the early diagnosis, projected prognosis, and therapeutic response of bladder cancer, informs the readers of the current status of proteomic-based biomarker findings, and suggests avenues for future work.